Rupestrian grasslands are vegetation complexes of the Cerrado biome (Brazilian savanna), exhibiting simultaneously great biodiversity and important open-pit mining areas. There is a strong demand for the conservation of remaining areas and restoration of degraded. This study evaluated, using next-generation sequencing, the diversity and ecological aspects of soil fungal communities in ferruginous rupestrian grassland areas preserved and degraded by bauxite mining in Brazil. In the preserved and degraded area, respectively, 565 and 478 amplicon sequence variants (ASVs) were detected. Basidiomycota and Ascomycota comprised nearly 72% of the DNA, but Ascomycota showed greater abundance than Basidiomycota in the degraded area (64% and 10%, respectively). In the preserved area, taxa of different hierarchical levels (Agaromycetes, Agaricales, Mortierelaceae, and Mortierella) associated with symbiosis and decomposition were predominant. However, taxa that colonize environments under extreme conditions and pathogens (Dothideomycetes, Pleoporales, Pleosporaceae, and Curvularia) prevailed in the degraded area. The degradation reduced the diversity, and modified the composition of taxa and predominant ecological functions in the community. The lack of fungi that facilitate plant establishment and development in the degraded area suggests the importance of seeking the restoration of this community to ensure the success of the ecological restoration of the environment. The topsoil of preserved area can be a source of inocula of several groups of fungi important for the restoration process but which occur in low abundance or are absent in the degraded area.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00248-023-02177-y | DOI Listing |
Background: Focused ultrasound (FUS)-induced blood-brain barrier opening (BBBO) is a technique for safely, non-invasively, and transiently opening the blood brain barrier in a targeted area of the brain. Pre-clinical and clinical studies have shown that FUS is capable of decreasing amyloid plaque load and stimulating neurogenesis in Alzheimer's Disease (AD) models, in addition to being safe for use in human patients. However, the effect of FUS-BBBO on neurons has not yet been characterized, despite its crucial role in cognition and regulating brain function.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brain Institute of Rio Grande do Sul - Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Although cognitive decline is a trait related to aging, some individuals are resilient to the aging process, defined as SuperAgers. Studying the neural underpinnings of SuperAgers may improve the understanding of AD pathology. In this study, our aim was to analyze amyloid and neurodegeneration imaging biomarkers in SuperAgers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Kobe University Graduate School of Medicine, Kobe City, Japan.
Background: In Japan, the number of patients with dementia is increasing and there is a shortage of human resources who can conduct detailed psychological examinations, and the development and implementation of new tools is essential for improving dementia care. Japan is one of seven sites across the globe focusing on healthcare system preparedness as part of the Davos Alzheimer's Collaborative Early Detection flagship program. As part of this program, Japan implemented new tools including a digital cognitive assessment (DCA) and blood-based biomarker (BBM) to increase rates of early detection of cognitive impairment.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Introduction: Lecanemab (LEQEMBI®), a humanized monoclonal antibody targeting Amyloid-beta (Aβ) protofibrils, received full FDA approval in July 2023 for treating early-stage Alzheimer's disease (AD). This abstract highlights Tel Aviv Medical Center's (TLVMC) specialized infrastructure for early AD diagnosis and treatment and includes presenting baseline characteristics of initial patients opting for LEQEMBI®.
Methods: Outlining our clinics' operational experience in establishing the Center for advanced treatments for AD, treatment protocol, and a descriptive analysis of baseline assessment data including demographics, baseline Magnetic-Resonance-Imaging (MRI), Cerebrospinal-fluid (CSF)/PET biomarkers, pre-treatment cognitive evaluations (Mini-Mental-State-Examination (MMSE)/Montreal-Cognitive-Assessment (MoCA)), and Apolipoprotein-E (APOE) status.
Alzheimers Dement
December 2024
Centre for Brain Research, Indian Institute of Science, Bangalore, Karnataka, India.
Background: India is unfortunately the "Diabetes Capital" of the world with estimated 101 million and 136 million patients suffering from diabetes and prediabetes respectively. Prediabetes is a transition state between euglycemia and diabetes. Although diabetes is associated with cognitive decline, studies that link prediabetes and cognition have been scarce and inconclusive especially from the Low and Middle Income (LMIC) countries.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!